Vera Therapeutics, Inc. (VERA)
VERA Stock Price Chart
Explore Vera Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze VERA price movements and trends.
VERA Company Profile
Discover essential business fundamentals and corporate details for Vera Therapeutics, Inc. (VERA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 May 2021
Employees
152.00
Website
https://veratx.comCEO
Gary Barrera
Description
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
VERA Financial Timeline
Browse a chronological timeline of Vera Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$1.60, while revenue estimate is $1.28m.
Earnings released on 7 May 2026
EPS came in at -$1.69 falling short of the estimated -$1.33 by -27.22%.
Earnings released on 26 Feb 2026
EPS came in at -$1.39 falling short of the estimated -$1.34 by -3.73%.
Earnings released on 5 Nov 2025
EPS came in at -$1.26 falling short of the estimated -$1.20 by -5.00%.
Earnings released on 5 Aug 2025
EPS came in at -$1.20 falling short of the estimated -$0.82 by -46.34%.
Earnings released on 6 May 2025
EPS came in at -$0.81 falling short of the estimated -$0.75 by -8.00%.
Earnings released on 26 Feb 2025
EPS came in at -$0.72 surpassing the estimated -$0.83 by +13.25%.
Earnings released on 7 Nov 2024
EPS came in at -$0.85 falling short of the estimated -$0.69 by -23.19%.
Earnings released on 8 Aug 2024
EPS came in at -$0.62 falling short of the estimated -$0.58 by -6.90%.
Earnings released on 9 May 2024
EPS came in at -$0.56 falling short of the estimated -$0.53 by -5.66%.
Earnings released on 20 Mar 2024
EPS came in at -$0.58 falling short of the estimated -$0.53 by -9.43%.
Earnings released on 9 Nov 2023
EPS came in at -$0.45 surpassing the estimated -$0.50 by +10.00%.
Earnings released on 10 Aug 2023
EPS came in at -$0.46 surpassing the estimated -$0.69 by +33.33%.
Earnings released on 11 May 2023
EPS came in at -$0.80 falling short of the estimated -$0.60 by -33.33%.
Earnings released on 28 Mar 2023
EPS came in at -$1.19 falling short of the estimated -$0.93 by -27.96%.
Earnings released on 9 Nov 2022
EPS came in at -$0.91 falling short of the estimated -$0.72 by -26.39%.
Earnings released on 10 Aug 2022
EPS came in at -$0.55 surpassing the estimated -$0.72 by +23.61%.
Earnings released on 16 May 2022
EPS came in at -$0.71 falling short of the estimated -$0.67 by -5.97%.
Earnings released on 24 Mar 2022
EPS came in at -$0.79 falling short of the estimated -$0.49 by -61.22%.
Earnings released on 10 Nov 2021
EPS came in at -$0.36 surpassing the estimated -$0.60 by +40.00%.
Earnings released on 16 Aug 2021
EPS came in at -$0.33 surpassing the estimated -$0.39 by +15.38%.
VERA Stock Performance
Access detailed VERA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
